Evidence map›Paper›PMID 33385441›Full record

ArticleJournal of microbiological methods2021

A novel bioreactor for the stable growth of Ureaplasma parvum and Ureaplasma urealyticum.

Derek Fleming, Melissa Karau, Robin Patel

Abstract read
In one paragraph

Article in Journal of microbiological methods, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. AntenatalInternational journal of molecular sciences · 2024
    Article
  2. MinisculeSustainable microbiology · 2024
    Review
  3. Flurofamide Prevention and Treatment ofMicrobiology spectrum · 2022
    Article
  4. Contribution of Uremia toMicrobiology spectrum · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Derek FlemingDivision of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, United States of America.
Melissa KarauDivision of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, United States of America.
Robin PatelDivision of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, United States of America; Division of Infectious Diseases, Department of Medicine, Mayo Clinic, Rochester, MN, United States of America. Electronic address: patel.robin@mayo.edu.

Funding

Ureaplasma urealyticum- and Ureaplasma parvum-associated hyperammonemiaR21AI150649 · NIAID · MAYO CLINIC ROCHESTER · PI PATEL, ROBIN · 2020 to 2021
$437k
NIAID NIH HHS R21 AI150649
6 · The paper itself

Abstract

Ureaplasma species, including Ureaplasma parvum and Ureaplasma urealyticum, are challenging to culture and maintain. Here, we describe a novel bioreactor for growing high-titer liquid Ureaplasma cultures in a stable manner.

Indexed as

BioreactorsHumansUreaplasmaUreaplasma InfectionsUreaplasma urealyticumBioreactorCultureGrowthUreaplasmaUreaplasma parvum

Identifiers

PMID33385441
PMCPMC7870580

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.